A UK-based contract research organization and a US AI startup are reshaping early-stage drug discovery by eliminating the biggest financial barrier biotech companies face: upfront costs for identifying promising drug candidates. The partnership between Concept Life Sciences and OpenBench combines artificial intelligence-driven virtual screening with wet-lab validation, allowing biotech firms to progress from target identification to validated hit series in as little as six months.

How Does the Success-Based Model Change Drug Discovery?

OpenBench operates on a fundamentally different financial model than traditional drug discovery services. Instead of charging clients upfront fees for research and screening work, the company performs virtual screening and initial research at its own expense, only collecting payment once validated hits are delivered to the client. This shifts early-stage financial risk away from biotech companies, which often operate with limited funding and need to preserve capital for later-stage development.

Concept Life Sciences extends this value proposition by adding its integrated "design-make-test" capabilities to the partnership. This means the combined service doesn't stop at identifying promising chemical candidates; it also includes medicinal chemistry expertise and in-vitro screening and validation to confirm that hits are actually developable.

What Makes This Approach Attractive in Today's Funding Environment?

The biotech industry is facing significant funding pressures. Companies need faster, lower-risk pathways to high-quality chemical starting points, yet traditional drug discovery requires substantial upfront investment with uncertain outcomes. The success-based model addresses this directly.

"Biotechs need faster, lower-risk paths to high-quality chemical starting points, particularly in today's funding environment. By combining OpenBench's success-based discovery model with our integrated development capabilities, we're giving clients a highly efficient route from target to validated, developable hits," said Steven L. Holshouser, Head of Business Development, North America at Concept Life Sciences.

Steven L. Holshouser, Head of Business Development, North America at Concept Life Sciences

Lewis Martin, Chief Scientific Officer at OpenBench, emphasized the core mission driving the partnership: "Our mission is to remove the biggest barrier in early discovery: upfront cost and uncertainty. We deliver validated chemical leads before our partners spend a dollar, enabling biotech companies to focus resources on advancing programmes with real potential".

Lewis Martin, Chief Scientific Officer at OpenBench

Steps to Accelerate Drug Discovery From Target to Hit Series

• AI-Powered Virtual Screening: OpenBench's structure-based platform uses artificial intelligence to computationally screen millions of potential compounds against a drug target, identifying the most promising candidates without requiring physical synthesis or testing.
• Integrated Medicinal Chemistry: Concept Life Sciences applies expert medicinal chemistry knowledge to refine and optimize the AI-identified candidates, ensuring they meet drug-like properties and can be synthesized efficiently.
• In-Vitro Validation: Promising compounds are synthesized and tested in laboratory assays to confirm they actually bind to the target and produce the desired biological effect before advancing to animal studies or clinical development.

This compressed timeline matters significantly in drug development. Traditional early-stage discovery can take 12 to 18 months or longer. By condensing the process to six months, biotech companies can validate their scientific hypotheses faster, make go/no-go decisions earlier, and reduce the overall time and cost to bring new medicines to patients.

The partnership also works across multiple therapeutic modalities and disease indications, meaning the approach isn't limited to a single type of drug or disease area. This flexibility allows biotech companies working on oncology, infectious disease, neurology, or other therapeutic areas to benefit from the same streamlined discovery process.

For the broader pharmaceutical industry, this collaboration signals a shift toward outcome-based partnerships in early-stage drug discovery. Rather than paying for effort or time spent, companies increasingly want to pay for results. This incentive alignment between service providers and clients encourages efficiency and reduces waste in the discovery process, ultimately accelerating the pace at which new drug candidates enter development pipelines.